https://scholars.lib.ntu.edu.tw/handle/123456789/633191
Title: | Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis | Authors: | Silverberg, Jonathan I Guttman-Yassky, Emma Thaçi, Diamant Irvine, Alan D Stein Gold, Linda Blauvelt, Andrew Simpson, Eric L CHIA-YU CHU et al., |
Keywords: | Allergy/Immunology | Allergy/Immunology General | Clinical Medicine | Clinical Medicine General | Dermatology | Dermatology General | Inflammatory Disease | T-Cells | Issue Date: | 23-Mar-2023 | Journal Volume: | 388 | Journal Issue: | 12 | Source: | The New England journal of medicine | Abstract: | Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα-interleukin-13Rα1 heterodimer receptor signaling complex. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633191 | ISSN: | 00284793 | DOI: | 10.1056/NEJMoa2206714 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.